Incidence of atrial fibrillation in a population with impaired glucose tolerance: The contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial
Roberto Latini, Lidia Staszewsky, Jie-Lena Sun, M. Angelyn Bethel, Marcello Disertori, Steven M. Haffner, Rury R. Holman, Futien Chang, Thomas D. Giles, Aldo P. Maggioni, Guy E.H.M. Rutten, Eberhard Standl, Laine Thomas, Gianni Tognoni, Robert M. Califf, John J.V. McMurray
Index: Am. Heart J. 166(5) , 935-40.e1, (2013)
Full Text: HTML
Abstract
Background The role of dysglycemia as an additional risk factor for atrial fibrillation (AF) is controversial. Therefore, it was of interest to assess risk factors for incident AF in a large, representative population of patients with cardiovascular risk factors and impaired glucose tolerance but not overt diabetes in NAVIGATOR.
Related Compounds
Related Articles:
2013-11-01
[Pak. J. Pharm. Sci. 26(6) , 1229-35, (2013)]
From evidence assessments to coverage decisions?: the case example of glinides in Germany.
2012-01-01
[Health Policy 104(1) , 27-31, (2012)]
Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.
2005-10-01
[Int. J. Clin. Pract. 59(10) , 1218-28, (2005)]
2012-02-01
[Diabetes Obes. Metab. 14(2) , 187-9, (2012)]
Nateglinide (Starlix): update on a new antidiabetic agent.
2003-01-01
[Int. J. Clin. Pract. 57(6) , 535-41, (2003)]